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Abstract
Introduction: The endoplasmic reticulum (ER) stress-response, evoked in mice by the overexpression of class I
major histocompatibility complex antigen (MHC-I), was proposed as a major mechanism responsible for skeletal
muscle damage and dysfunction in autoimmune myositis. The present study was undertaken to characterize in
more detail the ER stress-response occurring in myofibers of patients with inflammatory myopathies, focusing on
the expression and distribution of Grp94, calreticulin and Grp75, three ER chaperones involved in
immunomodulation.
Methods: Muscle biopsies were obtained from seven healthy subjects and 29 myositis patients, who were
subdivided into groups based on the morphological evidence of inflammation and/or sarcolemmal
immunoreactivity for MHC-I. Biopsies were analyzed by means of immunohistochemistry and western blot using
anti-Grp94, anti-calreticulin and anti-Grp75 specific antibodies. Parallel analyses on these ER chaperones were
conducted in rabbit and/or murine skeletal muscle after experimental induction of regeneration or systemic
inflammation.
Results: Upregulation of Grp94 characterized regenerating myofibers of myositis patients (P = 0.03, compared with
values detected in biopsies without signs of muscle regeneration) and developing and regenerating myofibers of
mouse muscles. Conversely, levels of calreticulin and Grp75 increased about fourfold and twofold, respectively, in
patient biopsies positive for sarcolemmal MHC-I immunoreactivity, compared with healthy subjects and patients
negative for both inflammation and MHC-I labeling (P < 0.005). Differently from calreticulin, the Grp75 level
increased significantly also in patient biopsies that displayed occasional sarcolemmal MHC-I immunoreactivity
(P = 0.002), suggesting the interference of other mechanisms. Experimental systemic inflammation achieved
in mice and rabbits by a single injection of bacterial lipopolysaccharide significantly increased Grp75 and
calreticulin but not MHC-I expression in muscles.
Conclusions: These results indicate that, in myositis patients, muscle regeneration and inflammation, in addition to
MHC-I upregulation, do evoke an ER stress-response characterized by the increased expression of Grp94 and Grp75,
respectively. The increase in the muscle Grp75 level in patients showing occasional immunoreactivity for
sarcolemmal MHC-I might be considered further as a broader indicator of idiopathic inflammatory myopathy.
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Idiopathic myositis represents a heterogeneous group of
chronic autoimmune disorders characterized by an
immunomediated inflammatory stress targeted to skeletal
muscles [1,2]. Although a large body of evidence supports
the role of innate and adaptive immune responses in the
pathogenesis of myositis [1,2], the lack of recovery of
muscle function observed in patients after immunosup-
pressive therapies has drawn special interest regarding
nonimmune mechanisms of muscle fiber damage [3].
Using transgenic mice, Nagaraju and colleagues showed
that the overexpression of class I major histocompatibil-
ity complex antigen (MHC-I) in skeletal muscle fibers
was responsible for the chronic activation of the endo-
plasmic reticulum (ER) stress-response and the develop-
ment of myositis [4]. Although comparable evidence for
a causal relationship between MHC-I upregulation and
myositis is presently lacking for the human disease, the
same authors demonstrated increased transcriptional
activity of genes responsive to ER stress, such as the ER
chaperone Grp78, in biopsies of myositis patients [4].
Data from the literature suggest that an increased
expression of ER chaperones might influence immune
mechanisms of fiber damage. ER chaperones favor the
assembly of peptide-MHC-I complex, or bind peptides
directly [5] - as occurs for Grp94 - and make cells
immunogenic after reaching surface localization [6-8] -
as described for Grp94, calreticulin and ERp57. Alterna-
tively, chaperones protect against immunological
d a m a g e ;f o ri n s t a n c e ,m t H s p 7 0 / G r p 7 5 / m o r t a l i n[ 9 ]p r o -
tects against complement-mediated cell death through
the shedding of the complement C5b-9 membrane
attack complex [10].
Except for sporadic inclusion-body myositis, where the
ER chaperones calnexin, calreticulin, Grp78, Grp94 and
ERp72 are upregulated and colocalize with intracellular
aggregates [11,12], the present knowledge about changes
in ER chaperone level and distribution among myofibers
of myositis patients is far from complete. In particular,
data concerning Grp94, calreticulin and Grp75 are pre-
sently lacking. A growing body of evidence indicates
that Grp94 plays a special role in muscle differentiation
and maturation [13-15]. Grp94 is required for meso-
derm induction and muscle cell differentiation [14], in
so far as it redistributes after Fyn-mediated tyrosine
phosphorylation in the secretory pathway [15], where it
is probably involved in processing of insulin-like growth
factor II [16], and, eventually, localizes at the cell sur-
face, where it participates in myotube formation [13].
Conversely, Grp75 expression in myofibers of human
and rat skeletal muscles appears related to oxidative
stress occurring either during training of both high and
low intensity [17] or during disuse [18].
The aim of the present study was therefore to investi-
gate the stress-response ongoing in muscle fibers of
patients affected with inflammatory myopathies, focus-
ing on Grp94, calreticulin and Grp75 expression and
distribution. Muscle biopsies obtained from 29 patients
were investigated by means of immunohistochemistry
and western blot, and results were compared with those
obtained from biopsies of healthy subjects. Comparable
analyses were then conducted on the experimental ani-
mal, in order to determine to which extent conditions
that accompany inflammatory myopathies, such as mus-
cle regeneration and systemic inflammation, do contri-
bute to myofiber ER stress-response.
Materials and methods
Human studies
Muscle biopsies were collected from seven young male
healthy subjects (mean age ± standard error of the
mean (SEM), 24 ± 1 years) in compliance with the prin-
ciples of the Helsinki Declaration [18], and from 29
patients positive for at least two of Bohan and Peter’s
criteria for inflammatory myopathy [19]. Data were
stripped of personally identifiable information. The
study was approved by the local ethics committee (Uni-
versity of Padova - Azienda Ospedaliera di Padova, Italy)
and written informed consent for study participation
was obtained from all the healthy subjects and from
patients.
Data concerning sex, disease duration, creatine phos-
phokinase levels in serum, the presence of muscle weak-
ness and of dermatomyositis skin rash, and the
positivity for electromyographic signs of myogenic dis-
ease are presented in Table 1. Muscle weakness was
defined according to Bohan and Peter criteria [19], as
symmetrical weakness of the limb-girdle muscles and
anterior neck flexor progressing over weeks to months,
reported by patients and confirmed by clinical evalua-
tion of muscle strength. The presence of antinuclear
autoantibodies was routinely determined by indirect
immunofluorescence on HEp2 cells and by immunoblot-
ting, as previously described [20,21]. A positive antinuc-
lear autoantibody test was defined as serum titer ≥ 160.
Myositis-specific autoantibodies, including anti-Mi-2,
anti-t-RNA synthetases and anti-signal recognition parti-
cle, were determined by a modified immunoblot assay
and indirect immunoprecipitation of cognate RNAs,
respectively [22]. Briefly, IgG antibodies to Mi-2 antigen
were detected by chemiluminescent immunoblot on 7%
SDS-PAGE-resolved nuclear extract from Raji cells.
Antibodies to RNA moieties were identified by protein
A-sepharose-assisted immunoprecipitation from patient
sera incubated with Jurkat cell lysate and analysis by sil-
ver staining of 7% polyacrylamide/urea gels.
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according to standard techniques [18]. The vastus later-
alis muscle was biopsied in volunteers and in the large
majority of patients (Table 1). From each biopsy, a sam-
ple of about 20 to 30 mg was removed, frozen in liquid
nitrogen and stored at -80°C for the present study. In
the case of patients, the remaining tissue was processed
for routine histology.
Animal experimental studies
Thirteen 1-day-old embryos and adult (30 g) male CD-1
mice were used. Samples from the liver, heart and tibia-
lis anterior muscle were excised from adult animals.
Samples were frozen in liquid nitrogen and stored at
-80°C. Eight adult mice were injected with 30 to 50 μl
of 50 mM BaCl2 in the tibialis anterior to induce muscle
degeneration and subsequent regeneration [23]. Animals
Table 1 Clinical, biochemical, immunological and immunohistological features of myositis patients
Muscle biopsy
c
Patient Sex Disease
duration
(months)
Muscle
weakness
DM skin
rash
Serum
CPK
a
(U/l)
EMG
b ANA
(IF)
b
Specific
autoantibodies
Inflammation
(site of biopsy)
Immunoreactivity
for
MHC-I εMy (%
of total)
Group I
1 F 4 P A 5027 + - Jo-1, RoSSA ++ (VL) ++ 36.60
2 F 15 P A 8570 + - Jo-1 ++ (D) ++ 35.50
3 F 8 P A 2762 - + Jo-1, RoSSA ++ (VL) + 15.50
4 F 168 P A 1100 + - - ++ (VL) ++ 1.09
5 M 29 P A 1125 - + Mi-2 ++ (VL) + 0.33
6 F 13 P P 292 + - - ++ (VL) ++ 0
7 F 3 P A 6705 + - Jo-1 + (VL) + 7.79
8 F 25 A A 1840 + + tRNA, RoSSA + (VL) ++ 2.00
9 M 25 P P 484 + - Mi-2 + (D) ++ 6.00
10 M 79 P A 535 - + U1RNP, RoSSA + (VL) ++ 36.60
11 F 9 P A 2762 + + - + (VL) + 15.55
12 F 13 P A 666 + - - + (TA) ++ 3.10
13 M 36 P A 2580 - + tRNA + (VL) + 0.20
14 F 103 P A 893 + + Jo-1 + (VL) + 0.06
Group II
15 F 27 P A 173 - + Jo-1 - (VL) + 0.13
16 M 72 P A 548 - - - - (VL) + 0
17 F 79 P A < 160 - + Ro/SSA - (D) ++ 0
18 M 33 P P 600 ND + - - (D) ++ 0.42
19 F 21 P A 221 + + Scl70, Ku - (VL) ++ 2.60
20 F 180 P A 1157 + + Jo-1 - (VL) + 0
21 F 67 P A 533 + + Mitotic apparatus - (D) + 1.1
Group III
22 F 237 P A 450 - - - - (VL) - 0.50
23 F 58 P A 43 + - - - (VL) - 0
24 F 237 P A 742 + - - - (D) - 0
25 M 24 P A 250 - - - - (VL) - 0
26 F 15 P A 1600 - - - - (VL) - 1.11
27 F 68 P A 628 + - - - (VL) - 0
28 M 33 P P 9868 + - - - (VL) - 0
29 F 24 P P 254 - + - - (VL) - 0
aValues correspond to those obtained at the time of muscle biopsy.
b+ and -, presence and absence of positive response, respectively.
c+ and ++, degree of
inflammation and MHC-I immunofluorescence, evaluated as described in Materials and methods; -, absence. DM, dermatomyositis; CPK, creatine phosphokinase;
EMG, electromyography; ANA (IF), antinuclear antibodies (immunofluorescence); MHC-I: class I major histocompatibility complex antigen; εMy (% of total),
percentage of myofibers positive for embryonic skeletal myosin on total biopsy fibers; F, female; M, male; P, present; A, absent; VL, vastus lateralis muscle;
D, deltoid muscle; TA, tibialis anterior muscle; ND, not done.
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western blot analysis, the superficial inflamed region of
the tibialis anterior was excised from the bulk of the
muscle; whereas for immunohistochemistry, the whole
muscle was taken.
To improve morphological preservation of the regen-
erating area, some mice were perfused under anesthesia
with PBS (NaCl 136 mM, KCl 2.68 mM, Na2HPO4
8 mM, KH2PO4 1.4 mM, pH 7.4), followed by 4% paraf-
ormaldehyde in PBS. Samples were then excised, incu-
bated in fixative for a further 2 hours at 4°C, rinsed with
PBS, cryoprotected with increasing concentrations of
sucrose and frozen.
Adult mice (n = 6) were treated with a single intraper-
itoneal injection of lipopolysaccharide (LPS) from Sal-
monella typhimurium (1 mg/kg; Sigma, Milan, Italy);
control animals (n = 6) were injected with saline. Ani-
mals were euthanized 48 hours after the injection, were
weighed and the tibialis anterior muscles were excised
and frozen. The LPS treatment of New Zealand rabbits
was described previously [24].
Five-week-old male mice from the C57BL/10 strain
(n = 5) and the dystrophin mutant mdx strain (n = 4)
were sacrificed, and the tibialis anterior and gastrocne-
mius muscles were excised and frozen.
Each experimental protocol followed internationally
recognized guidelines and was approved by the Animal
Care Committees of the University of Padova and the
Italian Ministry of Public Health.
Immunofluorescence and immunohistochemical analyses
Serial consecutive 12 μm cryosections were prepared
from frozen muscle samples, collected on gelatin-coated
glasses, and assayed for immunofluorescence and indir-
ect peroxidase immunohistochemistry, following pre-
viously described protocols.
Immunofluorescence labeling was used with fluores-
cein isothiocyanate (FITC)-labeled anti-human HLA-
ABC antibody (clone W6/32; Serotec, Oxford, UK). Sec-
tions were dried for 40 minutes, fixed for 15 minutes
with acetone at -20°C and dried. Cryosections were then
incubated at room temperature with 1:50 dilution of the
anti-HLA antibody, rinsed with PBS and mounted with
glycerol containing 0.01% 4,6-diamidino-2-phenylindole
dihydrochloride (DAPI) to counterstain nuclei. The pre-
sence of positive staining for MHC-I was evaluated with
a microscope equipped with fluorescence optics (Axio-
plan; Carl Zeiss Italia, Milan, Italy) and graded, according
to van der Pas and colleagues [25], as follows: grade -,
undetectable in myofibers, but present on capillaries;
grade +, both capillaries and myofiber sarcolemma are
stained, but the capillaries can still be identified easily;
and grade ++, both capillaries and myofiber sarcolemma
are stained, but capillaries can no longer be identified.
MHC-I immunostaining was further enhanced by
incubating sections for 30 minutes at 37°C with a 1:40
dilution of mouse anti-FITC immunoglobulins conju-
gated with peroxidase (Roche Diagnostic, Milan, Italy)
and developed as described below. Immunoreactivity for
murine MHC-I was visualized by incubating sections
with a 1:5 dilution of a monomorphic mouse monoclonal
antibody labeled with FITC (MCA2189F; Serotec), as
described above, and by subsequent amplification of anti-
body binding using the anti-FITC antibody conjugated
with peroxidase.
For indirect immunoperoxidase staining, sections were
processed as previously described [18,24,26]. Fiber typing
was achieved by comparison of serial sections labeled
with the monoclonal anti-slow b-myosin heavy chain
(My) antibody BA-D5 [18], which identifies type 1 fibers,
with those stained for the succinate dehydrogenase,
which discriminates between red and white myofibers
[27]. Regenerating myofibers were identified by reactivity
with the monoclonal anti-My antibody BF-G6, which
recognizes the human embryonic My isoform (εMy) [28].
Stress-protein expression was monitored with the follow-
ing antibodies: anti-Grp75 mouse monoclonal antibody
(SPS-825; Stressgen, Victoria, BC, Canada) [18]; anti-
Grp94 mouse monoclonal antibody (clone 3C4) [24,26]
and rabbit polyclonal antibody (SPA-851; Stressgen);
anti-calreticulin rabbit polyclonal antibodies (SPA-600;
Stressgen); and anti-CHOP/GADD153 rabbit polyclonal
antibodies (R-20; Santa Cruz Biotech, Heidelberg, Ger-
many). The presence of necrosis and autophagy was
determined using mouse monoclonal antibody for
human complement C9 (Novocastra Laboratories, New-
castle upon Tyne, UK) and anti-ubiquitin rabbit polyclo-
nal antibody (DakoCytomation, Milan, Italy),
respectively, as described by Kostin and colleagues [29].
Specificity of the staining was checked by processing
adjacent sections with the same protocol, except for the
use of nonimmune mouse or rabbit immunoglobulins
(1 μg/ml; Sigma) as the primary antibody.
Consistency of the immunostaining was validated by
independent analysis.
Western blotting
Procedures for western blotting were previously
described [18]. Equal amounts of muscle proteins were
tested with the following antibodies: anti-generic My,
mouse clone BF-46 [18]; anti-Grp94 3C4 [25]; anti-
Grp75 SPS-825 [18]; anti-calreticulin SPA-600; and anti-
a-actinin, mouse clone EA-53 (Sigma). Quantitative
densitometry was performed analyzing autoradiographic
bands using Image J software (NIH Bethesda, MD,
USA). Values were normalized to the corresponding
densitometric value of the Ponceau red staining of the
actin band [18] or of the a-actinin immunostaining.
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All data are expressed as the mean ± SEM. Statistical
analysis was performed utilizing unpaired analysis (one-
way analysis of variance (ANOVA) and post-hoc t-test).
P = 0.05 was set as the limit for significance. All these
analyses and linear regression analyses were performed
using the SigmaStat version 2.0 statistical package (Jan-
del, Germany).
Results
Human studies
Characterization of the patient cohort
All patients referred with longstanding muscle weakness
and showed increased levels of serum creatine phospho-
kinase, although positive electromyography for myogenic
suffering and positive histology for inflammation were
present in less than one-half of them (Table 1). Diagno-
sis of polymyositis or dermatomyositis was based on
Bohan and Peter’s criteria [19] (muscle weakness,
increased serum creatine phosphokinase levels, electro-
myography myopathic signs, positive histology, for the
former one, plus the presence of specific skin rash, for
the latter one). Connective tissue disease overlap syn-
drome was diagnosed in Patients 16, 17 and 19. Patients
23 and 25 were included in the study because of the
presence of two items from Bohan and Peter’s criteria
even though the diagnosis was myogenic suffering of
unknown origin. None of the patients was affected with
sporadic inclusion body myositis or genetic inflamma-
tory myopathy.
Patients were divided to three groups based on the
presence of inflammation at routine histology and
MHC-I immunofluorescence (Table 1). Group I
included patients with either intense (grade ++) or weak
(grade +) signs of inflammation and the presence of sar-
colemmal immunoreactivity for MHC-I, graded as
described in Materials and methods. Group II included
patients without histological signs of inflammation and
with sarcolemmal MHC-I immunoreactivity. Group III
included patients without both signs of inflammation
and immunoreactivity for MHC-I in muscle fibers. Pro-
longed and intense immunosuppressive treatment before
biopsy was excluded (Additional file 1). Both sexes were
represented in patient groups, with a predominance of
females. No statistically significant difference was
detected in average age among patient groups (mean
age ± SEM: 56.8 ± 4.2 years for Group I, 58.7 ± 6.9
years for Group II, and 57.8 ± 4.6 years for Group III).
The majority of patients enrolled in Groups I and II
showed the presence of myositis-specific antibodies; that
is, anti-tRNA-synthetases (anti-Jo-1 antibody) and -Mi-2
antigen, and/or myositis-associated autoantibodies
(Table 1). Conversely, none of these antibodies was
detected among patients of Group III.
The presence of muscle regeneration was evaluated on
biopsies by counting εMy-positive myofibers [28] and
expressing the value as the percentage of the total fiber
number (Table 1). There were more than 500 fibers in
the large majority of biopsies. The degree of regenera-
tion was higher in Group I patients, although it was not
always consistent with the histological evidence of
inflammation (Table 1). Regeneration was negligible in
patients of Groups II and III.
Biopsies from healthy volunteers corresponded to
Group 0 and were used as reference samples. No immu-
noreactivity for MHC-I was detected in muscle fibers
(not shown) and no muscle regeneration was observed
(Figure 1a).
Immunohistochemical analyses
Healthy subject biopsies (Group 0)
Immunohistochemistry for ER chaperones showed negli-
gible reactivity for Grp94 and Grp75 in muscle fibers of
biopsies from Group 0 subjects (Figures 1b and 2a for
Grp75), whereas antibodies against calreticulin labeled
w e a k l yan u m b e ro fm u s c l ef i b e r s( F i g u r e s1 ca n d2 m ) ,
which corresponded to about 60% of the type 1 popula-
tion and to 10% of the type 2 population one (data not
shown). Interstitial cells and vascular endothelial cells
were labeled by Grp94 and calreticulin antibodies
(arrows in Figure 1b, d). A faint cytosolic labeling for
the ER-stress-induced transcription factor CHOP [30]
was detected in type 2 fibers (Additional file 2A). Signs
of muscle death were apparently absent from biopsies of
Group 0 subjects (Additional file 2B,C). No fiber showed
positive immunoreactivity for ubiquitin, a marker of
proteasome overload and autophagic death [29], and for
serum complement protein C9, whose intracellular loca-
lization is indicative for the presence of necrosis [29].
Patient biopsies with a high percentage of regenerating
myofibers (Group I)
Different patterns of immunohistochemical labeling for
Grp94, Grp75 and calreticulin were detected in biopsies
from the patient groups (Figures 1 and 2). Figure 1d to
1i represents the staining observed in those Group I
patients who displayed a high percentage of regenerating
myofibers. Labeling for εMy was observed in variably
sized fibers: small reactive myofibers with centrally
located nuclei (arrowhead) corresponded to newly
formed myotubes, whereas larger myofibers corre-
sponded to more advanced maturation stages (Figure
1 d ) .T h em a j o r i t yo fεMy-positive myofibers showed
positive immunoreactivity for Grp94 (Figure 1e). A com-
parable picture was observed for calreticulin immunos-
taining, although the presence of labeling in adult
myofibers made less appreciable the decoration of
regenerating myofibers (Figure 1g). Some of the Grp94-
positive and calreticulin-positive myotubes also
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localized either in the nucleus (thick arrowhead), in the
cytosol (thick arrow), or at both locations (single arrow-
head) (Figure 1f; compare with Additional file 2A). A
minor proportion of CHOP-positive myotubes also
showed positive nuclear and cytosolic immunostaining
for ubiquitin (Figure 1i, thick arrows and thick arrow-
heads, respectively). The presence of intracellular posi-
tive staining for C9 was occasionally observed among
either CHOP-negative (Figure 1h, double arrowhead) or
CHOP-positive regenerating myofibers (data not
shown). Regenerating myofibers were not apparently
labeled by anti-Grp75 antibodies (data not shown; see
Additional file 3).
This same pattern of ER stress-protein immunoreactiv-
ity was also observed in regenerating myofibers in the
presence of nonprimary inflammatory myopathy, such as
Duchenne dystrophy [31] (see Additional file 3A to 3E).
Patient biopsies with a low percentage or absence of
regenerating myofibers (Groups I to III)
Nonregenerating myofibers of myositis patients
differed in immunoreactivity for Grp75 and calreticulin
Figure 1 Immunoreactivity for endoplasmic reticulum stress-markers in regenerating skeletal myofibers of myositis patients.S e r i a l
cryosections from biopsies of (a) to (c) a Group 0 subject (S6) and (d) to (i) a Group I myositis patient (P2), who displayed a high degree of
muscle regeneration, were stained with indirect immunoperoxidase with antibodies for embryonic skeletal myosin heavy chain (εMy), Grp94,
calreticulin (CRT), CHOP, complement 9 (C9) and ubiquitin (ubi). Thin arrows in (b) and (c) indicate interstitial cells reacting with anti-Grp94 and
anti-caltreticulin antibodies. Thick arrows in (d) to (i) indicate a regenerating muscle fiber (εMy-positive), which stained positively for Grp94 (e),
cytosolic CHOP (f), calreticulin (g) and ubiquitin (f). Thick arrowheads in (f) and (i) indicate a regenerating muscle fiber, which displayed nuclear
CHOP (f) and ubiquitin (i) immunoreactivity. Arrowheads in (d) to (i) indicate a regenerating muscle fiber, which displayed positive
immunoreactivity for Grp94 (e) and calreticulin (g), and both cytosolic and nuclear CHOP (f) and ubiquitin (i) staining. Double arrowheads in (d)
to (h) indicate the presence of positive C9 immunoreactivity, a marker of necrosis (h), in a regenerating muscle fiber, which displayed positive
immunoreactivity for Grp94 (e). Bar: 100 μm.
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immunoreactivity for Grp75 in cryosections from biopsies of (a) a Group 0 subject (S7) and of myositis patients ((b) P5 from Group I, (c) P20
from Group II, and (d) P22 from Group III) after immunoperoxidase staining. (e) to (h) Distribution of Grp75 immunoreactivity with indirect
immunoperoxidase in two additional Group I patients ((e) P7, and (g) P14) and that of type 1 fibers, identified by the immunoperoxidase
staining for b-myosin heavy chain (bMy) of adjacent cryosections (f) and (h). (i) to (l) Comparison of the distribution of Grp75 immunoperoxidase
labeling of two Group I patients, who differed for the degree of class I major histocompatibility complex antigen (MHC-I) immunoreactivity ((i)
P9, grade ++ MHC-I; (k) P14, grade + MHC-I) with the presence of sarcolemmal immunofluorescence for MHC-I (j) and (l). Thin arrows in (k) and
(l) indicate Grp75-positive and sarcolemmal MHC-I-positive fibers, whereas arrowheads indicate the presence of Grp75 immunoreactivity in
sarcolemmal MHC-I-negative ones. (m) to (p) Representative histochemical demonstration for calreticulin immunoperoxidase in cryosections
from biopsies of (m) a Group 0 subject (S1) and of myositis patients ((m) P6 from Group I, (o) P19 from Group II, and (p) P22 from Group III). Bar:
100 μm.
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an immunoreactivity pattern compatible with intracellu-
lar aggregates.
Staining for Grp75 appeared more intense in myofi-
bers of Group I and II patients, compared with those of
Groups 0 and III (Figure 2a to 2d). The increased reac-
tivity was detectable in the large majority of muscle
fibers, always encompassing type 1 and type 2A fiber
populations (Figure 2e to 2h), and appeared homoge-
neously distributed within the cytosol. Furthermore,
immunolabeling for Grp75 was not obligatorily related
to the presence of sarcolemmal MHC-I immunoreactiv-
ity, in so far as it was detected also in those Group I
and II patients who displayed MHC-I immunofluores-
cence only in a minor proportion of muscle fibers
(grade +) (Figure 2k, l - arrows indicate MHC-I-positive
fibers, arrowheads indicate negative fibers; compare with
Figure 2i, j). Grp75 immunostaining was also absent
from nonregenerating myofibers of nonprimary inflam-
matory myopathy, such as Duchenne dystrophy (Addi-
tional file 3A to 3E).
Calreticulin immunoreactivity also appeared to distri-
bute to a larger fiber population in biopsies of Group I
and Group II myositis patients (Figure 2m to 2o) than
that one of healthy subjects, whereas staining of biopsies
of Group III patients (Figure 2p) was comparable with
that of Group 0 subjects. We then investigated whether
a change in fiber type composition of patients of Group
Ia n dG r o u pI Im i g h te x p l a i nt he wider distribution of
calreticulin. The percentage of type 2A fibers signifi-
cantly decreased in both groups, compared with Group
0 (mean ± SEM: 23.94 ± 3.91%, 18.52 ± 3.90%, and
38.44 ± 3.95% for Group I, Group II, and Group 0,
respectively; n = 5, P = 0.01, ANOVA), whereas the
relative percentage of type 1 fibers increased by about
30%, albeit above the limit set for statistical significance
(mean ± SEM: 42.59 ± 4.30%, 46.89 ± 3.89%, and 33.56
± 3.93% for Group I, Group II, and Group 0, respec-
tively; n = 5, P = 0.06, ANOVA). Nevertheless, this
moderate increase in the type 1 fiber population did not
quite explain the wider distribution of calreticulin
immunoreactivity in biopsies of Group I and Group II
patients.
Nonregenerating myofibers of Group I patients showed
occasional immunoreactivity for CHOP (Additional file
4). Reactive fibers displayed also intense staining for both
calreticulin and Grp94 (data not shown) and were often
positive for C9 (arrows in Additional file 4) and ubiquitin
(data not shown). Except for these necrotic myofibers,
immunostaining for Grp94 appeared negligible in nonre-
generating myofibers (data not shown). Granular Grp94
immunoreactivity compatible with the presence of intra-
cellular aggregates was never observed.
Western blot analyses
The differences in ER stress-protein staining observed in
immunohistochemistry were validated by western blot
analysis (Figure 3).
Grp94
Increased signals for Grp94 were observed in those
patients of Group I who displayed the presence of
regenerating myofibers (mean ± SEM Grp94/actin ratio,
3.23 ± 1.27; n = 5), compared with values observed in
biopsies from Groups 0, I and II, in the absence of mus-
cle regeneration (mean ± SEM Grp94/actin ratio, 0.43 ±
0.05; n = 6, P = 0.03).
Grp75
The relative amount of Grp75 significantly increased
twofold in Group I patients, compared with Group 0
and Group III levels (Figure 3b; P = 0.01, ANOVA).
Interestingly, the level of statistical significance
increased when the comparison was performed consid-
ering only the Group I biopsies, which displayed the
lowest degree of muscle regeneration (mean ± SEM
Grp75/actin ratio of this subgroup, 2.26 ± 0.56; n = 7;
P < 0.005 compared with Group 0 values). Conversely,
Grp75 level detected in Group II patients did not differ
statistically from that observed in Group 0 subjects,
whereas it appeared significantly higher than that of
Group III patients (P = 0.02), whose average Grp75
level was lower than that of Group 0 (P = 0.056) (Fig-
ure 3b). Statistical evaluation of normalized Grp75 pro-
tein levels was then performed after redistribution of
Group I and Group II patients in subgroups based on
the grading of MHC-I immunoreactivity. Figure 3c
shows that biopsies from patients with a sarcolemmal
MHC-I expression detectable only in a proportion of
myofibers (grade +; n = 10) displayed significantly
increased Grp75 levels compared with values detected
in Group 0 and Group III subjects (P = 0.002,
ANOVA), similarly to those detected in biopsies with
ubiquitous distribution of sarcolemmal MHC-I immu-
noreactivity (grade ++).
Calreticulin
The relative amount of calreticulin significantly
increased about fourfold and twofold in patients of
Groups I and II, respectively, compared with the protein
levels detected in Group 0 and Group III biopsies (P =
0.003, ANOVA) (Figure 3a, d). When normalized calre-
ticulin protein levels were evaluated after redistributing
Group I and Group II patients in subgroups based on
the degree of MHC-I immunoreactivity, only the biop-
sies from patients with sarcolemmal MHC-I reactivity
detectable in every myofiber (grade ++) displayed a sig-
nificant increase in calreticulin levels, compared with
the levels detected in the other groups (P <0 . 0 0 1 ,
ANOVA) (Figure 3e).
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Page 8 of 15Figure 3 Expression levels of Grp94, Grp75 and calreticulin in patients’ biopsies. (a) Representative western blots of biopsies from Group 0
(S3), Group I (P1, P2, P12, P13), Group II (P20), and Group III patients (P25) stained for Grp94, Grp75, calreticulin (CRT) and actin. The percentage
of regenerating fibers (% reg) is indicated above each patient lane. (b) Histograms showing mean and standard error of the mean (SEM) for the
normalized Grp75 amount detected in Groups 0, I, II and III (n = 7, 14, 7 and 8, respectively). *Significant difference versus Groups 0 and III
(P = 0.01, analysis of variance (ANOVA)). (c) Histograms show mean and SEM of normalized Grp75 amount compared after redistribution of
Group I and Group II patients into two new groups based on grading of class I major histocompatibility complex antigen (MHC-I) sarcolemmal
immunostaining (see Table 1; n = 11 for MHC-I grade ++ group, 10 for MHC-I grade + group). *Significant difference versus Groups 0 and III
(P < 0.005, ANOVA). (d) Histograms showing mean and SEM of normalized calreticulin amount detected in Groups 0, I, II and III (n = 6, 14, 7
and 7, respectively). *Significant difference versus Groups 0 and III (P < 0.01, ANOVA). (e) Histograms showing mean and SEM of normalized
calreticulin amount compared after redistribution of Group I and Group II patients, as described for (c). *Significant difference versus all of the
groups (P < 0.01, ANOVA).
Vitadello et al. Arthritis Research & Therapy 2010, 12:R52
http://arthritis-research.com/content/12/2/R52
Page 9 of 15Animal experimental studies
In order to ascertain whether the differential upregula-
tion of these ER chaperones in regenerating and adult
myofibers of myositis patients reflected disease-related
mechanisms, their expression was investigated in experi-
mental animal models of muscle regeneration and sys-
temic inflammation.
Muscle regeneration
Because muscle regeneration recapitulates muscle differ-
entiation [32] and Grp94 showed a developmentally
regulated expression in rabbit skeletal muscle [24], we
investigated murine developing muscle by immunohisto-
chemical and western blot analyses. Cryosections from a
13-day embryo and from adult tibialis anterior muscle
showed positive staining for Grp94 in immature myofi-
bers (Figure 4a, arrow), whereas labeling was absent
from adult myofibers (Figure 4b). Western blot analysis
showed a single reactive polypeptide of apparent mole-
cular weight 99,000 in adult myocardium and liver sam-
ples; no reactivity was detected with adult skeletal
muscle homogenate (Figure 4c, lanes h, sk and l).
Muscle regeneration was then induced in the tibialis
anterior of adult mice [23]. Western blot analyses of
homogenates prepared from the superficial region of the
muscle after 4 days of regeneration showed the labeling of
a polypeptide with the same electrophoretic mobility of
Grp94 (Figure 4c, lane reg). Immunohistochemistry
showed the presence of an abundant number of regenerat-
ing muscle cells and myotubes, identified by their reactiv-
ity for εMy (Figure 4d). Regenerating myofibers reacted
strongly for Grp94 (Figure 4e), whereas they showed vari-
able immunoreactivity for CHOP (Figure 4f, arrows) and
calreticulin (data not shown). Positive staining for ubiqui-
tin was occasionally observed (data not shown).
Muscle regeneration was accompanied by increased
expression of MHC-I, as shown by the presence of cyto-
solic immunoreactivity in regenerating myofibers (Addi-
tional file 3F to 3G), consistent with that described in
the human [33].
Systemic inflammation
Nonregenerating muscle fibers from myositis patients
apparently did not vary their Grp94 expression. We
Figure 4 Grp94 and CHOP protein expression in regenerating murine myofibers. (a), (b) Indirect immunoperoxidase staining of murine
cryosections with the anti-Grp94 antibody. (a) Immature skeletal muscle from a 13-day mouse embryo; embryonic myofibers appear darkly
stained and the arrow indicates the presence of a sarcomeric pattern of labeling. (b) Transverse section of adult tibialis anterior muscle;
myofibers appear unlabeled; the reticular immunostaining around myofibers is due to the reactivity of the secondary antibody with mouse
immunoglobulins in the interstitial space. (c) Western blotting analysis with Grp94 of whole homogenates prepared from adult mouse
myocardium (h), tibialis anterior muscle (sk), liver (l) and the superficial region of a tibialis anterior muscle, 4 days after injury to induce muscle
regeneration (reg). Labeling of the myosin heavy chain (My) is shown as a reference for loading. (d) to (f) Indirect immunoperoxidase staining of
cryosections from adult tibialis muscle, 4 days after induction of muscle regeneration, with (d) monoclonal mouse anti-embryonic skeletal
myosin, (e) anti-Grp94 antibodies and (f) polyclonal rabbit anti-CHOP antibodies. Arrows in (d) to (f) indicate regenerating myofibers with
centrally located nuclei. Bar: 50 μm.
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be stressful for skeletal muscle without affecting Grp94
expression in myofibers. We previously reported that
systemic inflammation induced by a single LPS injec-
tion did not change Grp94 expression in rabbit adult
skeletal myofibers [24] - we therefore applied the same
experimental protocol to the mouse to investigate
whether Grp75 and calreticulin levels were affected. A
significant increase of Grp75 and calreticulin protein
levels (P =0 . 0 0 7a n dP = 0.004, respectively) was
observed in murine tibialis anterior muscles excised 48
hours after LPS administration, compared with muscles
of untreated animals (Figure 5a, b). Comparable results
were obtained using rabbit hindlimb muscles, excised
48 hours after a single admin i s t r a t i o no f4m g / k gL P S
[24] (Figure 5c, d). Exposure to LPS increased the
intensity and distribution of Grp75 immunoreactivity
within myofibers (Figure 5e, h), in the absence of his-
tological signs of inflammation and of MHC-I upregu-
lation (Additional file 5). A comparable, less evident
pattern of reactivity was observed for calreticulin (data
not shown).
At variance with LPS administration, the relative
amount of Grp75 did not appear to increase in other
conditions that might be accompanied by nonprimary
muscle inflammation, such as the mdx strain of murine
muscle dystrophy [34] (Additional file 3I). The mean ±
SEM of normalized Grp75 levels of control strain
C57BL/10 hindlimb muscles was 1.25 ± 0.32, whereas
that for mdx muscles was 0.83 ± 0.19 (P = 0.26).
Discussion
Our study shows that a large proportion of our myositis
patients displayed the presence of a multiple ER stress-
response in myofibers, characterized by the differential
expression of the ER chaperones Grp94 and Grp75. One
pattern of this ER response appeared to correlate with
the degree of muscle regeneration, whereas the second
pattern reflected the contribution of other influences,
probably of inflammatory origin, on idiopathic myositis.
Increased expression of Grp94 and calreticulin charac-
terized patients with a high percentage of regenerating
myofibers; experimental studies showed that this ER
stress-response occurred simultaneously with myotube
maturation, therefore lacking specificity for myositis.
Conversely, Grp75 levels increased in nonregenerating,
adult, myofibers of myositis patients who were positive
for sarcolemmal MHC-I immunoreactivity (Groups I
and II), but also involving MHC-I-negative myofibers.
Indeed, experimental animal investigations indicated
that mechanisms other than MHC-I overexpression are
responsible for the upregulation of Grp75, such as a sys-
temic cytokine release.
Increased Grp94 expression characterizes the
endoplasmic reticulum stress-response that accompanies
muscle regeneration
Different from most clinical studies, which consider
diagnosis as the starting point, we grouped myositis
patients on the presence or the absence of histological
signs of inflammation and of sarcolemmal MHC-I
immunoreactivity. Such an approach allowed us to cir-
cumscribe our attention to aspects, which have been
related to the occurrence of an ER stress-response in
muscle fibers [4].
In the present article we showed that the Grp94 level
increased in biopsies that displayed more than 3% of
regenerating fibers, and this association was further
experimentally validated in the laboratory mouse. The
crucial role played by Grp94 in muscle differentiation
and maturation has been recently recognized [13-15],
despite the scanty expression of this protein in adult
myofibers (present manuscript and [11,24,35]). Regener-
ating muscle fibers recapitulated differentiation, also dis-
playing increased immunoreactivity for calreticulin [8],
another ER chaperone, whose amount decreases from
early postnatal values and reduces further with aging
[36], being replaced by calsequestrin [37]. In addition,
regenerating myofibers showed nuclear and cytosolic
staining for CHOP, whose nuclear translocation was
described to occur during both in vitro and in vivo dif-
ferentiation of murine myogenic cells [38,39]. The ER
stress-response, which accompanies muscle differentia-
tion, has been proposed to be responsible for the natu-
rally occurring apoptosis during muscle development
[38]. Here we have shown that the ER stress-response
was present also in regenerating myofibers of patients
affected with Duchenne muscular dystrophy and in
those of dystrophic mdx mice, therefore reflecting the
maturation of skeletal muscle cells, which occurs inde-
pendently from the nature of the muscle disease.
Inflammatory stimuli and Grp75 upregulation in
myositis patients
At variance with Grp94, Grp75 protein levels increased
significantly in myositis biopsies with negligible levels of
regeneration, and especially in those displaying a
restricted sarcolemmal MHC-I immunoreactivity to a
few clusters of myofibers [40]. This observation sug-
gested that the upregulation of this protein occurred
independently from the presence of MHC-I immunor-
eactivity within the same fiber. In fact, Grp75 was not
detectable in regenerating myofibers, despite their
higher expression of MHC-I (present manuscript and
[33]). Grp75 is an Hsp70 analog, mostly localized within
ER and mitochondria [9]; in the present study, however,
the increase in Grp75 immunoreactivity involved
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Page 11 of 15Figure 5 Skeletal muscle expression of Grp75 and calreticulin after lipopolysaccharide injection in mice and rabbits. (a) Representative
western blots of tibialis anterior muscle of adult mice, left untreated or 48 hours after a single injection of lipopolysaccharide (LPS), labeled with
antibodies for Grp75 and calreticulin (CRT). Staining of a-actinin is shown as a reference for sample loading. (b) Histograms showing mean and
standard error of the mean (SEM) for the normalized amount of muscle Grp75 levels of untreated and LPS-treated mice. *Significant difference
versus untreated muscles (P < 0.01). (c) Representative western blots of hindlimb muscles of adult rabbits, left untreated or 48 hours after a
single injection of LPS, labeled with antibodies for Grp75 and CRT. Staining of a-actinin is shown as a reference for loading. (d) Histograms
showing mean and SEM for the normalized amount of muscle Grp75 levels of untreated and LPS-treated rabbits. *Significant difference versus
untreated muscles (P < 0.05). (e) to (h) Distribution of Grp75 immunoreactivity with indirect immunoperoxidase in hindlimb muscles of
(e) untreated and (g) LPS-treated rabbits. Adjacent sections (f) and (h) allow the comparison with the distribution of type 1 fibers, identified
by the immunoperoxidase staining for b-myosin heavy chain (bMy). Bar: 50 μm.
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Page 12 of 15glycolytic fibers too, and its expression could therefore
not be simply related to fiber mitochondrial content.
Grp75 is, at the same time, upregulated by and protec-
tive against oxidative stress [9,18]. A potential source of
o x i d a t i v es t r e s si ni d i o p a t h i cm y o s i t i si sr e p r e s e n t e db y
inflammation, through cytokines released from
macrophages.
We chose LPS as the proinflammatory stimulus to
experimentally reproduce systemic inflammation
because it acts on Toll-like receptor 4 of skeletal muscle
cells, inducing the release of chemoattractants [41], and
activates NF-B through the generation of reactive oxy-
gen species [42]. Interestingly, a single LPS injection
increased significantly Grp75 protein levels in skeletal
muscle fibers, in the absence of both Grp94 [24] and
MHC-I upregulation (present manuscript), proving that
systemic inflammatory stimuli do raise the expression of
this antioxidant stress-protein in muscle fibers. Further-
more, the lack of change in Grp75 levels in the presence
of nonprimary inflammation, such as that occurring
concomitantly with regeneration in the dystrophic mus-
cle, suggests a major role of systemic versus local
inflammatory stimuli in the upregulation of this stress-
protein in myositis.
In addition to being upregulated by oxidative stress
and involved in the antioxidant defense, increased
Grp75 levels might participate in and enhance myofiber
protection against complement-mediated lysis [10,43].
Although the contribution of autoantibodies in myositis
remains obscure [44-46], seven out of 10 patients of the
MHC-I grade + subgroup, who showed strongly
increased immunoreactivity for Grp75, were positive for
myositis-specific or associated autoantibodies. Until
now, no convincing demonstration of sarcolemmal
deposition of complement C5b-9 complex has been pro-
vided for major inflammatory muscle diseases - and
neither did we succeed in detecting it. The possibility
that Grp75 operates in removing this complex from the
cell surface, however, makes this negative finding more
likely.
Study limitations
We are aware that the present findings suffer from lim-
itations. Although the useo fm u s c l eb i o p s i e sf r o m
young healthy subjects as controls allowed us to exclude
unwanted effects secondary to trauma or neoplastic dis-
ease (systemic inflammation) on the cell stress-response,
this group differed in average age from the enrolled
patients. This feature might affect the correct evaluation
of the basal level of ER chaperone expression; the
slightly higher values of Grp75 levels detected in Group
0 patients compared with those of Group III patients,
however, would add even more relevance to the findings
concerning patients of Groups I and II.
Conclusions
Our data show that the two types of ER stress-response
detectable in the presence of autoimmune myositis
reveal the presence and the degree of muscle regenera-
tion, by means of increased Grp94 levels, and reveal the
influence of systemic stressing stimuli, probably of
inflammatory origin, which are responsible for the
increased expression of Grp75. Whereas one pattern of
ER stress-response occurs independently from the
pathogenesis of the disease, the increase in Grp75 levels
might represent a myositis-specific feature - especially
for those patients classified following Bohan and Peter’s
criteria and showing occasional immunoreactivity for
sarcolemmal MHC-I.
Additional file 1: Therapy of patients at time of biopsy. The table
illustrates patients’ individual therapy. F, female; M, male.
Additional file 2: Immunoreactivity for ER stress-markers in human
skeletal muscle. Serial cryosections from biopsies of a Group 0 subject
(S6; A to C) were stained with indirect immunoperoxidase with
antibodies for CHOP, complement 9 (C9) and ubiquitin (ubi). Bar: 100
μm.
Additional file 3: Immunoreactivity for ER stress-proteins and MHC-I
in nonprimary inflammatory myopathies. Serial cryosections from a
Duchenne patient [31] were stained with indirect immunoperoxidase
with antibodies for embryonic skeletal myosin heavy chain (εMy; A),
Grp94 (B), calreticulin CRT (C), MHC-I (D), Grp75 (E). Arrows indicate
regenerating myofibers positive for all markers, except Grp75. (F) to (H)
Indirect immunoperoxidase labeling of tibialis anterior muscle of mdx
mouse for εMy (F), Grp94 (G) and MHC-I (H) in a cluster of regenerating
myofibers. Bars: 100 μm. (I) Representative western blot analysis of mdx
and C57BL/10 hindlimb muscle homogenates with Grp75 and CRT.
Staining of a-actinin is shown as a reference for loading.
Additional file 4: ER stress-response and adult myofiber necrosis.
Serial cryosections from Group I myositis Patient P2 were stained with
indirect immunoperoxidase with antibodies for calreticulin CRT (A), CHOP
(B) complement 9 (C9), a marker of necrosis (C) and embryonic skeletal
myosin heavy chain (εMy; D). Bar: 100 μm.
Additional file 5: Immunoreactivity for MHC-I in animal
experimental model of systemic inflammation. Panels illustrate the
representative, indirect immunoperoxidase staining of murine MHC-I in
tibialis anterior cryosections of control (A) and LPS-treated (B) CD-1 mice.
Only endothelial cells of capillary and small vessels appear labeled. Bar:
50 μm.
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